Having found that GNA13-deficient SU-DHL4 cells are hypersensitive to the treatment with BCL2 inhibitors, we analyzed sensitivity of DLBCL cell lines to BCL2 inhibitors from published data41. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.